[How should anticoagulants be used in recurrent, ischemic and hemorrhagic brain infarctions?].
Leschke
M
M
Städtische Kliniken Esslingen, Fachbereich Kardiologie. m.leschke@kliniken-es.de
Klimek
W
W
D000284:Administration, Oral; D000367:Age Factors; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D000075202:Contraindications; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D012307:Risk Factors
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010644:Phenprocoumon; D001241:Aspirin